Search

Javier B Szwarcberg

from Sebastopol, CA
Age ~55
Get Report
Also known as:
Javier Dr Szwarcberg, Javier Bernardo Szwarcberg, Javier V Szwarcberg, Javier B Smulever, Javier G, Javier B, Javier R, Javier Y
Related to:
Erica Smulever, 54Jorge Szwarcberg
Connected to:
Jacques Szwarcbart, 62Mark Szwarcberg, 56Paula A Szwargulski, 65Kimberly A Szwartz, 48Lee E Szwast, 55Daniel J Szwaya, 66Paul R Szwayka, 37Myron J Szwec, 66Lisa A Szwech, 60Amy L Szwed, 55

Javier Szwarcberg Phones & Addresses

  • Sebastopol, CA
  • San Rafael, CA
  • Arnold, CA
  • 127 Roanoke St, San Francisco, CA 94131
  • 2173 Bunker Hill Dr, San Mateo, CA 94402 (650) 212-7005
  • Brisbane, CA
  • Morristown, NJ
  • Saint Louis, MO
  • Calabasas, CA
  • 2173 Bunker Hill Dr, San Mateo, CA 94402

Work

Position: Medical Professional

Education

Degree: Associate degree or higher

Business Records

Name / Title
Company / Classification
Phones & Addresses
Javier Szwarcberg
Principal
Inter Mune Pharmaceuticals Inc
Commercial Physical Research
1710 Gilbreth Rd, Burlingame, CA 94010

Publications

Us Patents

Pirfenidone Treatment For Patients With Atypical Liver Function

View page
US Patent:
7635707, Dec 22, 2009
Filed:
Sep 3, 2009
Appl. No.:
12/553292
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Mateo CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A61K 31/445
US Classification:
514327
Abstract:
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.

Methods Of Administering Pirfenidone Therapy

View page
US Patent:
7816383, Oct 19, 2010
Filed:
Jan 8, 2010
Appl. No.:
12/684879
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A61K 31/44
A61K 31/15
A01N 33/24
A01N 33/02
A61K 31/135
US Classification:
514350, 514354, 514640, 514646
Abstract:
The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Methods Of Administering Pirfenidone Therapy

View page
US Patent:
7910610, Mar 22, 2011
Filed:
Oct 8, 2010
Appl. No.:
12/901245
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A01N 33/24
A01N 33/02
A61K 31/44
A61K 31/15
A61K 31/135
US Classification:
514350, 514354, 514640, 514646
Abstract:
The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Methods Of Administering Pirfenidone Therapy

View page
US Patent:
8013002, Sep 6, 2011
Filed:
Mar 16, 2011
Appl. No.:
13/049894
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A01N 33/24
A01N 33/02
A61K 31/44
A61K 31/15
A61K 31/135
US Classification:
514350, 514354, 514640, 514646
Abstract:
The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Pirfenidone Therapy And Inducers Of Cytochrome P450

View page
US Patent:
8084475, Dec 27, 2011
Filed:
Jan 8, 2010
Appl. No.:
12/684543
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A61K 31/44
US Classification:
514350, 514354, 514345
Abstract:
The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.

Methods Of Administering Pirfenidone Therapy

View page
US Patent:
8318780, Nov 27, 2012
Filed:
Sep 2, 2011
Appl. No.:
13/224589
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A01N 33/24
A01N 33/02
A61K 31/44
A61K 31/15
A61K 31/135
US Classification:
514350, 514354, 514640, 514646
Abstract:
The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Pirfenidone Treatment For Patients With Atypical Liver Function

View page
US Patent:
8592462, Nov 26, 2013
Filed:
Dec 6, 2011
Appl. No.:
13/312746
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A61K 31/44
US Classification:
514345, 514350, 546261, 546262
Abstract:
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.

Pirfenidone Treatment For Patients With Atypical Liver Function

View page
US Patent:
8609701, Dec 17, 2013
Filed:
Nov 9, 2009
Appl. No.:
13/128569
Inventors:
Williamson Ziegler Bradford - Ross CA, US
Javier Szwarcberg - San Francisco CA, US
Assignee:
Intermune, Inc. - Brisbane CA
International Classification:
A01N 43/40
A61K 31/44
US Classification:
514345, 514350, 546261, 546262
Abstract:
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
Control profile
Javier B Szwarcberg from Sebastopol, CA, age ~55 Get Report